Acid-suppressing agents and risk for clostridium difficile infection in pediatric patients

Clinical Pediatrics

Volumn 54, Issue 11, 2015, Pages 1102-1106

  Brown, Katelyn E ^a   Knoderer, Chad A ^b   Nichols, Kristen R ^b   Crumby, Ashley S ^c  

^a PURDUE UNIVERSITY   (United States)

^b BUTLER UNIVERSITY   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Clostridium difficile; diarrhea; H2RA; pediatric; PPI

Indexed keywords

LANSOPRAZOLE; RANITIDINE; ANTIULCER AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ARTICLE; CASE CONTROL STUDY; CHILD; CHILDHOOD DISEASE; CLOSTRIDIUM DIFFICILE INFECTION; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT RESPONSE; ADOLESCENT; CLOSTRIDIUM INFECTIONS; DRUG EFFECTS; INFANT; PEPTOCLOSTRIDIUM DIFFICILE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; RISK FACTOR;

ADOLESCENT; ANTI-ULCER AGENTS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; INFANT; MALE; POLYMERASE CHAIN REACTION; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84941550715     PISSN: 00099228     EISSN: 19382707     Source Type: Journal    
DOI: 10.1177/0009922815569201     Document Type: Article

References (20)

1. Nylund CA, Goudie A, Garza JM, Fairbrother G, Cohen MB,. Clostridium difficile infection in hospitalized children in United States. Arch Pediatr Adolesc Med. 2011; 165: 451-457.
2. Khanna S, Baddour LM, Huskins WC,. The epidemiology of Clostridium difficile infection in children: a population-based study. Clin Infect Dis. 2013; 107: 89-95.
3. Deshpande A, Pant C, Anderson MP, Donskey CJ, Sferra TJ,. Clostridium difficile infection in the hospitalized pediatric population: increasing trend in disease incidence. Pediatr Infect Dis J. 2013; 32: 1138-1140.
4. Sammons JS, Toltzis P, Zaoutis TE,. Clostridium difficile infection in children. JAMA Pediatr. 2013; 167: 567-573.
5. Sammons JS, Localio R, Xiao R, Coffin SE, Zaoutis T,. Clostridium difficile infection is associated with increased risk of death and prolonged hospitalization in children. Clin Infect Dis. 2013; 57: 1-8.
6. Kim J, Smathers SA, Prasad P, Leckerman KH, Coffin S, Zaoutis T,. Epidemiological features of Clostridium difficile -associated disease among inpatients at children"s hospitals in the United States, 2001-2006. Pediatrics. 2008; 122: 1266-1270.
7. Samady W, Bush R, Pong A, Andrews A, Fisher E,. Predictors of Clostridium difficile infections in hospitalized children. J Hosp Med. 2014; 9: 94-98.
8. Shivashankar R, Khanna S, Kammer PP,. Clinical factors associated with development of severe-complicated Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013; 11: 1466-1471.
9. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK,. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012; 107: 1011-1019.
10. Tleyjeh IM, Abdulhak AB, Riaz M,. The association between histamine 2 receptor antagonist use and Clostridium difficile infection: a systematic review and meta-analysis. PLoS One. 2013; 8: e56498.
11. Turco R, Martinelli M, Miele E,. Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection. Aliment Pharmacol Ther. 2010; 31: 754-759.
12. Pohl JF, Patel R, Zobell JT,. Clostridium difficile infection and proton pump inhibitor use in hospitalized pediatric cystic fibrosis patients. Gastroenterol Res Pract. 2011; 2011: 345012.
13. Blank P, Zaoutis T, Fisher B, Troxel A, Kim J, Aplenc R,. Trends in Clostridium difficile infection and risk factors for hospital acquisition of Clostridium difficile among children with cancer. J Pediatr. 2013; 163: 699-705.
14. Rexach CE, Tang-Feldman YJ, Cantrell MC, Cohen SH,. Epidemiologic surveillance of Clostridium difficile diarrhea in a freestanding pediatric hospital and a pediatric hospital at a university medical center. Diagn Microbiol Infect Dis. 2006; 56: 109-114.
15. Nylund CA, Eide M, Gorman GH,. Association of Clostridium difficile infections with acid suppression medications in children. J Pediatr. 2014; 165: 979-984.
16. Pohl JF,. Clostridium difficile infection and proton pump inhibitors. Curr Opin Pediatr. 2012; 24: 627-631.
17. Schutze GE, Willoughby RE, Committee on Infectious Diseases; American Academy of Pediatrics. Clostridium difficile infection in infants and children. Pediatrics. 2013; 131: 196-200.
18. Jump RL, Pultz MJ, Donskey CJ,. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidicity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile -associated diarrhea? Antimicrob Agents Chemother. 2007; 51: 2883-2887.
19. Wolters Kluwer Health, Inc. Famotidine: histamine H2 antagonists. Facts and comparisons. http://factsandcomparisons.com. Accessed March 2, 2014.
20. Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH, Wang TC,. Who is using chronic acid suppression therapy and why? Am J Gastroenterol. 2003; 98: 51-58.